文献速递类风湿关节炎

抗CarP与抗PAD3抗体单独或联合RF和ACPA对类风湿关节炎严重程度的预测价值

Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究基于瑞士临床质量管理登记库中有生物样本的851例确诊RA患者和516例疾病对照,分析抗CarP和抗PAD3抗体单独或联合RF和ACPA对严重RA结局的预测价值。结果显示抗PAD3抗体与更高的DAS28和影像学损伤评分相关,而抗CarP未见与RA结局指标的差异。

要点

  • 抗PAD3阳性RA患者基线DAS28更高(4.2 vs 3.7;P=0.005)且影像学损伤更重(14.9 vs 8.8;P=0.02)。
  • 抗PAD3、RF IgM和ACPA联合阳性者基线影像学评分显著高于双血清阳性组(P=0.04)。
  • 任意两种上述自身抗体阳性者10年影像学进展显著大于全部阴性者(P=0.02)。

核心结论

  • 抗PAD3抗体与RA患者更高的疾病活动度和关节损伤评分相关。
  • 抗CarP抗体与RA结局指标未见差异。

研究设计与样本

  • 基于瑞士临床质量管理登记库中有生物样本的851例确诊RA患者和516例疾病对照(axSpA 320例,PsA 196例)的队列分析。
  • 检测RF、ACPA、抗CarP和抗PAD3抗体,分析各自身抗体与基线及纵向DAS28、HAQ和影像学损伤(Ratingen)的关联。

主要发现

  • 抗CarP和抗PAD3抗体分别存在于22.4%和10.7%的整个RA人群,以及13.2%和3.8%的RF和ACPA双血清阴性患者中。
  • 基线时抗PAD3阳性RA患者较阴性者DAS28更高(4.2 vs 3.7;P=0.005)且影像学损伤显著更多(14.9 vs 8.8;P=0.02)。
  • 在ACPA阴性亚组中,抗PAD3阳性患者基线Ratingen评分显著更高(P=0.01)。
  • 抗PAD3、RF IgM和ACPA联合阳性者基线影像学评分显著高于双血清阳性组(P=0.04)。
  • 任意两种上述自身抗体阳性者10年影像学进展显著大于全部阴性者(P=0.02)。

关键数值与推荐

  • 抗PAD3阳性RA患者基线DAS28为4.2 vs 3.7(P=0.005),Ratingen评分为14.9 vs 8.8(P=0.02)。
  • ACPA阴性亚组中抗PAD3阳性者基线Ratingen评分显著更高(P=0.01)。
  • 抗PAD3、RF IgM和ACPA联合阳性者基线影像学评分显著高于双血清阳性组(P=0.04)。
  • 任意两种自身抗体阳性者10年影像学进展显著大于全部阴性者(P=0.02)。

临床怎么用

  • 在RA患者中检测抗PAD3抗体可能有助于识别疾病活动度和关节损伤风险更高的患者。
  • 抗PAD3联合RF和ACPA检测可进一步分层评估基线影像学损伤风险。

局限性

  • 研究基于登记库中有生物样本的患者,可能存在选择偏倚。
  • 抗CarP与RA结局指标未见差异,其预测价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to analyse the predictive value of anti-carbamylated protein (anti-CarP) and anti-peptidyl-arginine deiminase type-3 (anti-PAD3) antibodies, alone or in combination with RF and ACPA, to identify patients at high risk of developing severe RA outcomes. METHODS: Patients within the Swiss Clinical Quality Management registry with a biobank sample were tested for RF, ACPA, anti-CarP, and anti-PAD3 antibodies. We examined the association of each autoantibody with DAS28, HAQ and radiographic damage (Ratingen) at baseline and longitudinally. RESULTS: Analyses included 851 established RA patients and 516 disease controls [axial spondyloarthritis (axSpA = 320) and PsA (196)]. Anti-CarP and anti-PAD3 antibodies were, respectively, present in 22.4% and 10.7% of the whole RA population, and in 13.2% and 3.8% of the RF and ACPA double seronegative patients. At baseline, RA patients with anti-PAD3 had higher DAS28 (4.2 vs 3.7; P= 0.005) and significantly more radiographic damage (14.9 vs 8.8; P= 0.02) than anti-PAD3-negative patients. In the ACPA-negative subgroup, baseline Ratingen scores were significantly higher in anti-PAD3-positive patients (P= 0.01). The combination of anti-PAD3, RF IgM, and ACPA was associated with significantly higher baseline radiographic scores than the double seropositive group (P= 0.04). The presence of any two of the previous autoantibodies was associated with significantly greater radiographic progression over 10 years than if all were absent (P= 0.02). There were no differences in RA outcome measures with regards to anti-CarP. CONCLUSIONS: Anti-PAD3 antibodies are associated with higher disease activity and joint damage scores in RA patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lamacchia C, Courvoisier DS, Jarlborg M, et al. Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 33502443. doi:10.1093/rheumatology/keab050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。